Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of PEComas: A Review of the Role of Radiotherapy.

Cancers·2026
Same author

Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling.

NPJ precision oncology·2026
Same author

Fertility Preservation Needs of Men Undergoing Cancer Treatment: An Explorative Qualitative Study.

Current oncology (Toronto, Ont.)·2026
Same author

In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Reply to "Prognostic factors in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors: Clinical implications beyond NF1 status".

Cancer·2026
Same author

Intermediate Risk Rhabdomyosarcoma in Very Young Children (Less Than or Equal to 24 Months) Treated on the Prior Children's Oncology Group Protocol ARST1431.

Pediatric blood & cancer·2026

Related Experiment Video

Updated: Jan 31, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K

Rhabdomyosarcoma.

Stephen X Skapek1,2, Andrea Ferrari3, Abha A Gupta4

  • 1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA. Stephen.Skapek@UTSouthwestern.edu.

Nature Reviews. Disease Primers
|January 9, 2019
PubMed
Summary

Rhabdomyosarcoma (RMS) is a common childhood cancer. Understanding its subtypes, molecular drivers, and risk factors is key to optimizing treatment and improving outcomes for affected children.

More Related Videos

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.9K
Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish
09:39

Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish

Published on: December 26, 2014

11.3K

Related Experiment Videos

Last Updated: Jan 31, 2026

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

2.9K
Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish
09:39

Normal and Malignant Muscle Cell Transplantation into Immune Compromised Adult Zebrafish

Published on: December 26, 2014

11.3K

Area of Science:

  • Pediatric Oncology
  • Cancer Biology
  • Sarcoma Research

Background:

  • Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children.
  • It is a high-grade neoplasm originating from skeletal myoblast-like cells.
  • RMS requires control of primary and disseminated disease for curative therapy.

Purpose of the Study:

  • To provide a comprehensive overview of current knowledge on Rhabdomyosarcoma.
  • To detail the epidemiology, pathophysiology, and clinical management of RMS.
  • To highlight opportunities for translating biological insights into improved patient outcomes.

Main Methods:

  • Review of decades of clinical and basic research on RMS.
  • Analysis of molecular mechanisms driving different RMS subtypes.
  • Integration of clinical, pathological, and molecular features for risk stratification.

Main Results:

  • Two major RMS subtypes exist, driven by distinct molecular mechanisms.
  • Multifaceted therapy, including chemotherapy, surgery, and radiation, is guided by risk stratification.
  • Current understanding incorporates diagnostics, risk-based care, and management of late effects.

Conclusions:

  • Optimized clinical care for RMS has evolved through extensive research.
  • Understanding RMS subtypes and molecular drivers is crucial for tailored treatment.
  • Future research translating biological insights holds promise for enhancing cure rates and survivor well-being.